Literature DB >> 9661644

Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome.

L C Morin-Papunen1, R M Koivunen, C Tomás, A Ruokonen, H K Martikainen.   

Abstract

Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS). The aim of this study was to evaluate whether the improvement of ovarian function achieved by metformin therapy is associated with changes in leptin concentrations. Twenty-six obese women with PCOS were treated with 500 mg metformin, x 3 daily, for 2 months; and 12 women continued the therapy for 4-6 months. A significant decrease in the serum leptin level was observed after 2 months of treatment in the whole study group (29.2 +/- 12.7 ng/mL vs. 25.7 +/- 10.9 ng/mL, P = 0.03). In the 12 women treated for 4-6 months, the mean serum leptin concentration decreased after 2 months (38.6 +/- 9.3 ng/mL vs. 30.2 +/- 8.1 ng/mL; P = 0.004) but slightly increased after 4-6 months of treatment (33.4 +/- 15.7 ng/mL; not significant). These results indicate that insulin sensitizing therapy with metformin decreases the leptin concentrations in obese PCOS women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661644     DOI: 10.1210/jcem.83.7.4944

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients.

Authors:  Manouchehr Nakhjavani; Afsaneh Morteza; Firuzeh Asgarani; Abnoos Mokhtari; Alireza Esteghamati; Omid Khalilzadeh; Ghazaleh Rahbari
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 2.  Insulin resistance, polycystic ovary syndrome and metformin.

Authors:  M Pugeat; P H Ducluzeau
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

4.  Pharmacological and non-pharmacological strategies for obese women with subfertility.

Authors:  Seyed Abdolvahab Taghavi; Madelon van Wely; Shayesteh Jahanfar; Fatemeh Bazarganipour
Journal:  Cochrane Database Syst Rev       Date:  2021-03-25

5.  Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis.

Authors:  Wen Kong; Xun Niu; Tianshu Zeng; Meixia Lu; Lulu Chen
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

6.  Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer.

Authors:  Ameet K Mishra; Christopher R Parish; Ma-Li Wong; Julio Licinio; Anneke C Blackburn
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

7.  Intracerebroventricular injection of metformin induces anorexia in rats.

Authors:  Chang Koo Lee; Yoon Jung Choi; So Young Park; Jong Yeon Kim; Kyu Chang Won; Yong Woon Kim
Journal:  Diabetes Metab J       Date:  2012-08-20       Impact factor: 5.376

8.  Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.

Authors:  Jemma Anderson; Alexia S Peña; Thomas Sullivan; Roger Gent; Bronwen D'Arcy; Timothy Olds; Brian Coppin; Jennifer Couper
Journal:  BMC Pediatr       Date:  2013-07-16       Impact factor: 2.125

9.  Co-Administration of Metformin and N-Acetyl Cysteine Fails to Improve Clinical Manifestations in PCOS Individual Undergoing ICSI.

Authors:  Ebrahim Cheraghi; Malek Soleimani Mehranjani; Mohammad Ali Shariatzadeh; Mohammad Hossein Nasr Esfahani; Zahra Ebrahimi
Journal:  Int J Fertil Steril       Date:  2014-07-08

10.  Serum leptin and body composition in polycystic ovarian syndrome.

Authors:  Tayfun Alper; Hakki Kahraman; Mehmet Bilge Cetinkaya; Filiz Yanik; Gulizar Akcay; Abdulkerim Bedir; Erdal Malatyalioglu; Arif Kokcu
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.